Cancer Care Ontario
Action Cancer Ontario | eClaims

Eligibility Form

Durvalumab - Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Chemoradiation

(This form must be completed before the first dose is dispensed.)

1. Patient Profile

* Surname: .....
* Given Name: .....
* OHIN: ..... * Chart Number: _____
* Postal Code: _____
* Height (cm): ..... * Weight (kg): _____
* BSA (m^2): ..... * Gender: ○ Male ○ Female ○ Other
* Date of Birth: ..... _____ ..... (Day Month Year)
* Site:
* Attending Physician (MRP- Most Responsible Physician): _____

Requested Prior Approval ☐ Yes * Patient on Clinical Trial ○ Yes ○ No

Other (specify): .....

Specify Arm:
○ Standard of care arm ○ Experimental arm
○ Blinded / Unknown

Prior Approval Request

* Select the appropriate prior approval scenario:

- ○ 1-Unknown primary (submit pathology report and clinic note)
- ○ 2-Clinical document review (identify the patient history that needs to be reviewed against eligibility criteria in Additional Comments below)
- ○ 3-Regimen modification - schedule (complete questions a and b)
- ○ 4-Regimen modification - drug substitutions (complete questions a and c)
- ○ 5-Withholding a drug in combination therapy from start of treatment (complete questions d, e and f)
- ○ 6-Maintenance therapy delay (submit clinic note)
- ○ 7-Prior systemic therapy clinical trials (complete question g)
- ○ 8-Modification due to supply interruption/drug shortage
- ○ 9-Supplemental doses requested
- ○ 10-COVID-19 pandemic: use of durvalumab after sequential chemoradiation only if access to radiation (or chemotherapy resources) is limited
- ○ Other (specify)

.....

All relevant supporting documentation must be submitted at the time of prior approval. Documentation may include a pathology report, clinic note, and/or CT scans.

a. Co-morbidities / toxicity / justification:

.....

b. Intended regimen schedule: .....

c. Intended regimen: .....

d. Drug(s) to be held: .....

e. Rationale for holding drug(s): .....

f. Intention to introduce drug at a later date?

- ☐ Yes

g. Prior clinical trial identifier (e.g., NCT ID, trial name) and treatment description (e.g., arm, drug/regimen): .....

h. Anticipated date of first treatment: ..... Day ..... Month ..... Year

i. Additional comments:

.....

2. Eligibility Criteria

- Durvalumab is used for the treatment of patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) following curative intent platinum-based concurrent chemoradiation therapy. ☐ Yes

3. Baseline Information

a. ECOG Performance Status at the time of enrolment ○ 0 ○ 1 ○ 2

b. Is the patient transitioning from non-publicly funded means? ○ Yes ○ No

c. If yes, please indicate the number of doses received through non-publicly funded means:

○ 1	○ 2	○ 3	○ 4	○ 5	○ 6	○ 7	○ 8	○ 9
○ 10	○ 11	○ 12	○ 13	○ 14	○ 15	○ 16	○ 17	○ 18
○ 19	○ 20	○ 21	○ 22	○ 23	○ 24	○ 25		

4. Funded Dose

Durvalumab 10 mg/kg intravenously (IV) every 2 weeks or
Durvalumab 20 mg/kg IV every 4 weeks, up to a maximum of 1500 mg every 4 weeks.

Treatment should continue until disease progression or unacceptable toxicity up to a maximum of 12 months (i.e., 26 cycles if administered every 2 weeks or 13 cycles if administered every 4 weeks), whichever comes first.

[ST-QBP regimen code: DURV]

5. Notes

1. Patients whose disease progresses while on durvalumab are not eligible for anti-PD-1/anti-PD-L1 funding for advanced non-small cell lung cancer.

2. Patients who require a temporary treatment interruption may complete the remaining doses (up to the maximum number of cycles noted in the Funded Dose section) as long as the disease has not progressed.

3. Treatment with durvalumab should be initiated within 6 weeks of completion of concurrent chemoradiation.

6. FAQs

1. **My patient is currently receiving durvalumab through non-publicly funded means. Can my patient be transitioned over to receive funding through the New Drug Funding Program (NDFP)?**

   Provided the funding criteria were met at the time of treatment initiation and the patient's disease has not progressed, your patient may be eligible for continued coverage of durvalumab through NDFP. Funding is for a total of 26 cycles if administered every 2 weeks or 13 cycles if administered every 4 weeks, regardless of funding source.

2. **My patient completed the full course of durvalumab, but has now progressed. Is my patient eligible for funding of anti-PD-1 agents for advanced NSCLC?**

   Patients who discontinue durvalumab without disease progression and have a disease-free interval of 6 months or greater may be eligible for one line of atezolizumab, nivolumab, or pembrolizumab for advanced NSCLC.

3. **My patient received sequential chemotherapy and radiation, and I would like to treat them with durvalumab as consolidation therapy. Will this be funded?**

   Durvalumab is only funded for patients who receive concurrent chemoradiation. Patients who receive sequential chemotherapy and radiation are not eligible for durvalumab under this policy.

7. Supporting Documents

None required at time of enrolment.

In the event of an audit or upon request, the following should be available to document eligibility:

- o Clinic note indicating the chemoradiation used.
- o CT scans every 3 to 6 months, along with clinic notes indicating no disease progression.
- o For instances where there is pseudoprogression, a clinic note documenting the assessment and decision to continue, and the subsequent CT scan confirming no disease progression.

Signature of Attending Physician (MRP-Most Responsible Physician): _____

Day Month Year